Nuritas announce peer reviewed publication of world’s first AI discovered anti-inflammatory
Nuritas, the world leader in artificial intelligence-based natural molecule discovery, has published an independent peer reviewed scientific paper in Foods Journal. The paper outlines the discovery of natural rice-based peptides clinically proven to impact inflammation and improve physical test results in an elderly population.
Whilst these peptides are found within food, critically, their health benefit cannot be achieved by simply eating rice. Nuritas’ unique approach is able to identify these previously undiscovered peptide molecules amongst the billions of peptides in rice and then unlock their biological functionality. The ensuing natural products that Nuritas creates have the capability to prevent the development of lifestyle and metabolic disease.
The paper entitled “An artificial intelligence characterised functional ingredient derived from rice inhibits TNF-α and significantly improves physical strength in an inflammaging population” describes the process of peptide discovery using AI, followed by laboratory based testing and carrying out a human clinical trial. Exciting data from this trial shows that significant reductions in TNF-α (an inflammatory cytokine) in the blood corresponds with significant improvements in a number of standardised physical tests. These physical tests can be useful predictors of the likelihood of future falls, for example.
Discovered using our proprietary ground-breaking AI technology NπΦ (pronounced N-pi-fy or Nuritas Peptide Finder), the new natural rice product shows huge potential to improve the health of the globally ageing population. “Inflammaging” – the term used for age related chronic inflammation, increases the risk of a multitude of health conditions including muscle wastage, strength loss and general immunity.
“The results or the trial couldn’t come at a more significant time. With COVID-19 heightening general awareness of inflammation and cytokines, discovering a natural product which can assist is a hugely significant finding for the team. This is as a result of years of hard work refining our AI and machine learning platform in combination with our expert in-house laboratory and team of world class scientific advisors” commented Dr Nora Khaldi, Nuritas Founder and CEO.
Neil Foster, head of strategic partnerships at Nuritas said, “2020 is looking to be a seminal year in the way that consumers value and are taking responsibility for their health. Consumers are also becoming far more discerning, they want natural but also the latest science and efficacy that can be measured or better still felt.” Foster added, “Against this backdrop Nuritas is launching three new products, had multiple papers published with some incredible clinical results. The interest and appetite for the Nuritas offering of fully characterised natural products that work is incredible”.
This is the latest in a series of peer reviewed papers recently published from Nuritas discoveries including the first clinically tested AI discovered anti-aging molecule PeptiYouthTM, as well as PeptiStrongTM, a product addressing muscle wasting., all important health areas needing new solutions.